Ilaris 150 MG/ML vialml
Ended Awarded Last action
- Contract number
- SPE2DR26FGHL5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $29,286
Award facts
- Contract value 100% obligated
- $29,286.02 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $29,286.02 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for ILARIS 150 mg/ml vial supplies. The award, issued on January 27, 2026, with an ultimate completion date of February 18, 2026, carries no set-aside designation, indicating the contractor competed in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499,999,999 contract awarded in November 2025 that positions the company as a regional prime vendor contractor supporting Department of Defense pharmaceutical supply needs.
As a critical supplier within the federal military medical supply chain, DMS Pharmaceutical Group leverages its established performance to fulfill specialized pharmaceutical requirements for DoD healthcare operations globally. The company's extensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals spanning oncology treatments, immunosuppressants, emergency medications, and routine drugs. The PPV-G GEN V program, part of a broader $30.3 billion acquisition strategy, authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders to multiple regional prime vendors for recurring medical supply needs at military healthcare facilities worldwide, with DMS Pharmaceutical Group's track record on numerous prior delivery orders demonstrating its capability to support this critical mission.
Quick answers
Who was awarded contract SPE2DR26FGHL5?
SPE2DR26FGHL5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 27, 2026.
How much is contract SPE2DR26FGHL5 worth?
The government has obligated $29,286 on SPE2DR26FGHL5.
Is contract SPE2DR26FGHL5 an order under another contract?
Yes. SPE2DR26FGHL5 is a delivery order under SPE2DR25D9363, an indefinite delivery contract.
Was contract SPE2DR26FGHL5 competed?
The extent of competition for SPE2DR26FGHL5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award